Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Latest Information Update: 19 Dec 2023
At a glance
- Drugs Fostamatinib (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis; Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- 23 Mar 2023 Status changed from recruiting to discontinued.
- 26 Oct 2022 Planned End Date changed from 31 May 2024 to 31 May 2025.
- 26 Oct 2022 Planned primary completion date changed from 31 May 2024 to 31 May 2025.